AGA Medical commences enrollment in AMPLATZER Cardiac Plug clinical trial AGA Medical Holdings.

President and ceo of AGA Medical John Barr commented, Beginning enrollment in this research is a substantial milestone for AGA Medical. We believe that our gadget to close the remaining atrial appendage is an innovative solution to a complicated and debilitating problem for patients and the health care system. With our first individual enrolled, we are advancing a study that demonstrates our continuing commitment to developing high-value items that can change the standard of care for patients, as well as providing doctors with scientifically audio data, Barr continued.Abram C. Shmerling suffered for more than 11 years, succumbing to the condition in 2006. We are committed to maintaining the integrity and tranquility of the existing neighborhood, while providing an unprecedented degree of care and array of services for people suffering from these diseases in Middle Tennessee, said Shmerling. We made numerous efforts to incorporate land use methods that benefit the neighborhood, both voluntarily and at our neighbors’ request, imposing construction limitations that considerably exceed current zoning restrictions. Examples include: increasing setbacks from 5′ and 20′ to 30′-38′ and 100′, designating a two acre Metro Nashville greenway easement parallel to Sugartree Creek, reducing impervious surface ratio from .7 to .5, providing a substantial property line scenery buffer, capping building height, and reducing overall building mass.

PRESS RELEASE Statement attributed to: Andrew W.